ImpediMed Gets Positive Reimbursement Report

In a key step towards the achievement of its prospectus milestones, ImpediMed Ltd is pleased to announce the major findings of quantitative reimbursement research into the US market showing both positive reactions by US healthcare payers to ImpediMed’s bioimpedance technology and the need for a technology specific category one Current Procedural Terminology (CPT) code for the future.